Cargando…

Clinical consequences of upfront pathology review in the randomised PORTEC-3 trial for high-risk endometrial cancer

BACKGROUND: In the PORTEC-3 trial, women with high-risk endometrial cancer (HR-EC) were randomised to receive pelvic radiotherapy (RT) with or without concurrent and adjuvant chemotherapy (two cycles of cisplatin 50 mg/m(2) in weeks 1 and 4 of RT, followed by four cycles of carboplatin AUC5 and pacl...

Descripción completa

Detalles Bibliográficos
Autores principales:	de Boer, S M, Wortman, B G, Bosse, T, Powell, M E, Singh, N, Hollema, H, Wilson, G, Chowdhury, M N, Mileshkin, L, Pyman, J, Katsaros, D, Carinelli, S, Fyles, A, McLachlin, C M, Haie-Meder, C, Duvillard, P, Nout, R A, Verhoeven-Adema, K W, Putter, H, Creutzberg, C L, Smit, V T H B M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834053/ https://www.ncbi.nlm.nih.gov/pubmed/29190319 http://dx.doi.org/10.1093/annonc/mdx753

Ejemplares similares

Molecular Classification Predicts Response to Radiotherapy in the Randomized PORTEC-1 and PORTEC-2 Trials for Early-Stage Endometrioid Endometrial Cancer
por: Horeweg, Nanda, et al.
Publicado: (2023)

Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial
por: de Boer, Stephanie M, et al.
Publicado: (2018)

Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy
por: León-Castillo, Alicia, et al.
Publicado: (2020)

p53 immunohistochemistry in endometrial cancer: clinical and molecular correlates in the PORTEC-3 trial
por: Vermij, Lisa, et al.
Publicado: (2022)

Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial
por: de Boer, Stephanie M, et al.
Publicado: (2019)

Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy
por: Wortman, B. G., et al.
Publicado: (2018)

PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer
por: van den Heerik, Anne Sophie V M, et al.
Publicado: (2020)

HER2 Status in High-Risk Endometrial Cancers (PORTEC-3): Relationship with Histotype, Molecular Classification, and Clinical Outcomes
por: Vermij, Lisa, et al.
Publicado: (2020)

Patients' and clinicians' preferences for adjuvant chemotherapy in endometrial cancer: an ANZGOG substudy of the PORTEC-3 intergroup randomised trial
por: Blinman, Prunella, et al.
Publicado: (2016)

Selecting Adjuvant Treatment for Endometrial Carcinoma Using Molecular Risk Factors
por: Wortman, Bastiaan G., et al.
Publicado: (2019)

A Hyper-Viscoelastic Continuum-Level Finite Element Model of the Spinal Cord Assessed for Transverse Indentation and Impact Loading
por: Rycman, Aleksander, et al.
Publicado: (2021)

Prediction model for regional or distant recurrence in endometrial cancer based on classical pathological and immunological parameters
por: Versluis, M A, et al.
Publicado: (2015)

Statement of the Uterus Committee of the Gynaecological Oncology Working Group (AGO) on the PORTEC-3 study
por: Emons, Günther, et al.
Publicado: (2018)

Data related to architectural bone parameters and the relationship to Ti lattice design for powder bed fusion additive manufacturing
por: McGregor, Martine, et al.
Publicado: (2021)

Impact of upfront randomization for postoperative treatment on quality of surgery in the CRITICS gastric cancer trial
por: Claassen, Y. H. M., et al.
Publicado: (2018)

Microsatellite instability derived JAK1 frameshift mutations are associated with tumor immune evasion in endometrioid endometrial cancer
por: Stelloo, Ellen, et al.
Publicado: (2016)

Virtual reality as a learning tool in spinal anatomy and surgical techniques
por: Chen, T, et al.
Publicado: (2021)

Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistry
por: Vermij, Lisa, et al.
Publicado: (2023)

Examining the Diagnostic Yield of Tumour Testing and Qualifying Germline Concordance for Hereditary Cancer Variants in Patients with High-Grade Serous Carcinoma
por: Goebel, Emily A., et al.
Publicado: (2022)

Prevalence and Prognosis of Lynch Syndrome and Sporadic Mismatch Repair Deficiency in Endometrial Cancer
por: Post, Cathalijne C B, et al.
Publicado: (2021)

Limited impact of intratumour heterogeneity on molecular risk assignment in endometrial cancer
por: van Esterik, Manouk, et al.
Publicado: (2017)

The Role of Radiotherapy in Endometrial Cancer: Current Evidence and Trends
por: Creutzberg, Carien L., et al.
Publicado: (2011)

Adherence Tracking With Smart Watches for Shoulder Physiotherapy in Rotator Cuff Pathology: Protocol for a Longitudinal Cohort Study
por: Burns, David, et al.
Publicado: (2020)

Laser Ablation Inductively Coupled Plasma Mass Spectrometry: An Emerging Technology for Multiparametric Analysis of Tissue Antigens
por: Hutchinson, Robert W., et al.
Publicado: (2015)

Correlation between pelvic bone marrow radiation dose and acute hematological toxicity in cervical cancer patients treated with concurrent chemoradiation
por: Kumar, T, et al.
Publicado: (2019)

Cisplatin is retained in the cochlea indefinitely following chemotherapy
por: Breglio, Andrew M., et al.
Publicado: (2017)

Tertiary lymphoid structures critical for prognosis in endometrial cancer patients
por: Horeweg, Nanda, et al.
Publicado: (2022)

Treatment preferences and involvement in treatment decision making of patients with endometrial cancer and clinicians
por: Kunneman, M, et al.
Publicado: (2014)

ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up
por: Colombo, Nicoletta, et al.
Publicado: (2016)

DEBATE UPFRONT vs DELAYED TRANSPLANT
por: Gay, F.
Publicado: (2023)

Meta‐analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer
por: Versteijne, E., et al.
Publicado: (2018)

Upfront Enzyme Replacement via Erythrocyte Transfusions for PNP Deficiency
por: Eichinger, Anna, et al.
Publicado: (2021)

Preferential Phosphorylation of R-domain Serine 768 Dampens Activation of CFTR Channels by PKA
por: Csanády, László, et al.
Publicado: (2005)

Close observation versus upfront treatment in hepatocellular carcinoma: are the exception points worth the risk?
por: Tholey, Danielle M, et al.
Publicado: (2017)

Upfront Daratumumab With Lenalidomide and Dexamethasone for POEMS Syndrome
por: Gavriatopoulou, Maria, et al.
Publicado: (2020)

Surgery for Crohn’s disease: upfront or last resort?
por: Ahmed Ali, U, et al.
Publicado: (2022)

Upfront Next Generation Sequencing in Non-Small Cell Lung Cancer
por: Kuang, Shelley, et al.
Publicado: (2022)

The in- or exclusion of non-breast cancer related death and contralateral breast cancer significantly affects estimated outcome probability in early breast cancer
por: Nout, R. A., et al.
Publicado: (2007)

Impact of Endoscopic Ultrasonography on (18)F-FDG-PET/CT Upfront Towards Patient Specific Esophageal Cancer Treatment
por: Hulshoff, J. B., et al.
Publicado: (2017)

The Addition of Chemoradiation to Adjuvant Chemotherapy is Associated With Improved Survival Following Upfront Surgical Resection for Pancreatic Cancer With Nodal Metastases
por: Altman, Ariella M., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_smkglahh4fkpl0r8p6338begj1